Cost Considerations Drive Lean Technology in Biomanufacturing
News
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-15-2017
Volume 2017 eBook
Issue 1
Pages: s4-s7
Manufacturing for originator molecules is restricted by regulations, but drug makers can exploit newer technologies for the manufacture of biosimilars.
The approval of biosimilars for the US market has created a need for more efficient manufacturing processes.
Manufacturers are developing processes for cost efficiency and reliability using newer technology to compete with innovator products manufactured with legacy processes.
Innovations include more productive cell lines, single-use systems, and powerful analytical methods.
Download
Pharmaceutical Technology’s 2017 Biologics and Sterile Drug Manufacturing eBook.
Articles in this issue
Clean, Disinfect, and Validate
Kill the Bioburden, Not the Biological Indicator
Cold Chain Logistics for Personalized Medicine: Dealing With Complexity
Ensuring the Biological Integrity of Raw Materials
Getting Biopharmaceutical Tech Transfer Right the First Time
Developing an Injectable Compound for a Dual- Chamber Delivery System
Case Study: Retrofitting Two New High-Purity Water Systems
Single-Use Bioreactors Have Reached the Big Time
Parallel Processing
Cost Considerations Drive Lean Technology in Biomanufacturing
Recent Videos
Related Content
